Expertise in
103
conditions

Dr. Mohammad M. Jamal

Gastroenterology
26501 Rancho Pkwy S, 
Lake Forest, CA 
On Staff At
Offers Telehealth
41 Years of Experience
Expertise in
103
conditions
26501 Rancho Pkwy S, 
Lake Forest, CA 

Overview

Mohammad Jamal is a Gastroenterologist in Lake Forest, California. Dr. Jamal has been practicing medicine for over 41 years is highly rated in 103 conditions, according to our data. His top areas of expertise are Gastrointestinal Bleeding, Gallstones, Choledocholithiasis, Endoscopy, and Gastrectomy.

His clinical research consists of co-authoring 4 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution

Damascus University , 1981 - 1985, 1985

Residency

University of Iowa, Hospitals & Clinics , Internal Medicine , 1988 - 1989

Specialties

Gastroenterology

Licenses

Internal Medicine in NV

Board Certifications

American Board Of Internal Medicine

Fellowships

University of New Mexico Medical School , 1990 - 1991

Hospital Affiliations

Corona Regional Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Inland Empire Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

Mj Medical Group Inc
26501 Rancho Pkwy S, Lake Forest, CA 92630
Other Locations
Gastroenter
2097 Compton Ave, Corona, CA 92881
Basim Z. Abdelkarim, M.d., Inc.
1310 San Bernardino Rd, Upland, CA 91786

Additional Areas of Focus

Dr. Jamal has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
Enrollment Status: Completed
Publish Date: June 21, 2024
Intervention Type: Drug
Study Drug: Ontamalimab
Study Phase: Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 307)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 307)
Enrollment Status: Terminated
Publish Date: March 31, 2022
Intervention Type: Drug, Other
Study Drug: Ontamalimab
Study Phase: Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)
Enrollment Status: Completed
Publish Date: January 14, 2022
Intervention Type: Other, Drug
Study Phase: Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 306)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 306)
Enrollment Status: Terminated
Publish Date: May 11, 2021
Intervention Type: Other, Biological
Study Phase: Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 302)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 302)
Enrollment Status: Terminated
Publish Date: April 26, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Enrollment Status: Completed
Publish Date: February 11, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Phase 2 Study to Assess the Efficacy, Safety, and Tolerability of Velusetrag for the Treatment of Diabetic or Idiopathic Gastroparesis
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Phase 2 Study to Assess the Efficacy, Safety, and Tolerability of Velusetrag for the Treatment of Diabetic or Idiopathic Gastroparesis
Enrollment Status: Completed
Publish Date: April 17, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 6 Less Clinical Trials

4 Total Publications

Mirizzi-Induced Bouveret's Syndrome: Revelations of Timely Surgical Intervention.
Mirizzi-Induced Bouveret's Syndrome: Revelations of Timely Surgical Intervention.
Journal: Case reports in gastroenterology
Published: September 27, 2021
Similar Doctors
Expertise in
26
conditions
Dr. Tarek I. Hassanein
Gastroenterology
Expertise in
26
conditions
Dr. Tarek I. Hassanein
Gastroenterology

Southern California Liver Centers Inc

San Clemente, CA 
 (14.9 miles away)
619-522-0399
Experience:
44+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Tarek Hassanein is a Gastroenterologist in San Clemente, California. Dr. Hassanein has been practicing medicine for over 44 years is highly rated in 26 conditions, according to our data. His top areas of expertise are Hepatitis C, Hepatitis, Non-Alcoholic Fatty Liver Disease, Endoscopy, and Liver Transplant.

Expertise in
53
conditions
Dr. Jason Samarasena
Gastroenterology
Expertise in
53
conditions
Dr. Jason Samarasena
Gastroenterology

UCI Health H.H. Chao Comprehensive Digestive Disease Center

101 The City Dr S Bldg 22C, 
Orange, CA 
 (14.4 miles away)
888-717-4463
Languages Spoken:
English
See accepted insurances

Jason Samarasena is a Gastroenterologist in Orange, California. Dr. Samarasena is highly rated in 53 conditions, according to our data. His top areas of expertise are Barrett Esophagus, Jaundice, Gastroesophageal Reflux Disease (GERD), Endoscopy, and Colonoscopy.

Expertise in
21
conditions
Dr. Norah Terrault
Gastroenterology
Expertise in
21
conditions
Dr. Norah Terrault
Gastroenterology

Los Angeles-Gi Liver Clinic

1510 San Pablo St Ste 200, 
Los Angeles, CA 
 (40.7 miles away)
323-442-8894
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Norah Terrault is a Gastroenterologist in Los Angeles, California. Dr. Terrault is highly rated in 21 conditions, according to our data. Her top areas of expertise are Hepatitis, Hepatitis C, Hepatitis B, Liver Transplant, and Hepato-Pancreato-Biliary Surgery.

Frequently Asked Questions about Dr. Mohammad M. Jamal

How do I make an appointment with Dr. Mohammad M. Jamal?

You can book an appointment with Dr. Mohammad M. Jamal by calling their office at 949-415-7747. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Mohammad M. Jamal a top-rated expert for Gastrointestinal Bleeding?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Mohammad M. Jamal is classified as an Distinguished expert for Gastrointestinal Bleeding, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Mohammad M. Jamal specialize in?

While Dr. Mohammad M. Jamal is a Gastroenterology, they have specific expertise in Gastrointestinal Bleeding, Gallstones, and Choledocholithiasis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Gastroenterology.

Does Dr. Mohammad M. Jamal participate in research or clinical trials?

Yes. Dr. Mohammad M. Jamal has published 4 articles and abstracts on conditions like Gastrointestinal Bleeding. You can view a list of Dr. Mohammad M. Jamal's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Mohammad M. Jamal accept my insurance?

Dr. Mohammad M. Jamal accepts most major insurance plans, including Aetna and Alignment Health Plan. We recommend calling the office directly at 949-415-7747 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Jamal's expertise for a condition
ConditionClose
    View All 32 Distinguished Conditions
    View All 71 Advanced Conditions
    View All 46 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile